Biotech Knockoffs Lure Novartis
“A big pharma player is expanding its generics business. Expect others to follow
The divide between those making brand-name drugs and those producing generics is about to become a bit less clear. “
Biotech returning to favor
“After a nearly four-year slowdown, money is beginning to flow again into the biotechnology sector. But it’s more a trickle than a torrent. “
Drug firms in United States, Europe move biotech work to India
“Drug makers in the United States and Europe are increasingly moving clinical trials and research work to India, which helped Indian firms earn US$54 million in revenue in the last fiscal year…”
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Recent Comments